MAGALY ALONSO: Open Payments
NPI 1861458226 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,638 in 72 payments from 14 companies in 2025. Trend: 2023 $1,463 · 2024 $1,311 · 2025 $1,638
Food & beverage: $1,638
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 18 | $387 |
| ABBVIE INC. | 17 | $373 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $225 |
| Vanda Pharmaceuticals Inc. | 4 | $101 |
| Otsuka America Pharmaceutical, Inc. | 4 | $100 |
| ACADIA Pharmaceuticals Inc | 1 | $91 |
| Axsome Therapeutics, Inc. | 3 | $84 |
| E.R. Squibb & Sons, L.L.C. | 3 | $81 |
| Lundbeck LLC | 3 | $71 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
Products named: INGREZZA, VRAYLAR, TRINTELLIX, REXULTI, NUPLAZID, Auvelity, COBENFY, FANAPT.
Industry payments across FL — which companies pay providers there.
